Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | IGFBP3 | P17936 | 3/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29883306 | 1.00 | KDM4E (0.50) | KDM4EGLAHPGDHSD17B10MEN1 | |
| SCHEMBL9327979 | 0.79 | IGFBP3 (0.52) | KDM4EGLAHPGDHSD17B10MEN1 | |
| SCHEMBL4768998 | 0.79 | KDM4E (0.52) | KDM4EGLAHPGDHSD17B10MEN1 | |
| SCHEMBL3205661 | 0.79 | IGFBP3 (0.49) | KDM4EGLAHPGDHSD17B10MEN1 | |
| SCHEMBL1990776 | 0.78 | KDM4E (0.50) | KDM4EGLAHPGDHSD17B10MEN1 | |
| SCHEMBL31165745 | 0.78 | MEN1 (0.55) | KDM4EGLAHPGDHSD17B10MEN1 | |
| SCHEMBL30420994 | 0.78 | ALDH1A1 (0.50) | KDM4EGLAHPGDHSD17B10MEN1 | |
| SCHEMBL30023908 | 0.78 | KDM4E (0.50) | KDM4EGLAHPGDHSD17B10MEN1 | |
| SCHEMBL1202533 | 0.78 | ALDH1A1 (0.50) | KDM4EGLAHPGDHSD17B10MEN1 | |
| SCHEMBL12146113 | 0.76 | HTR3A (0.44) | KDM4EHPGDHSD17B10ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105377251-A | Mobilizing agents and uses thereof | MATER MEDICAL RES INST LTD | 2016-03-02 | — | — | CN | disclosed |
| WO-2013030358-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030358-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2013-03-07 | — | — | WO | disclosed |
| EP-1012166-B1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2003-10-29 | — | — | EP | disclosed |
| US-6420438-B1 | FOR THERAPY OF THROMBOTIC DISEASE, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY | TULARIK LIMITED (GB) | 2002-07-16 | — | — | US | disclosed |
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6262069-B1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-1012166-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | Protherics Molecular Design Limited (GB) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999011657-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | CTRL, HPN, CTSL | KDM4E 3526/4885GLA 597/4885HPGD 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.